S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:EPZM

Epizyme (EPZM) Stock Forecast, Price & News

$1.52
+0.04 (+2.70%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.48
$1.53
50-Day Range
$0.42
$1.52
52-Week Range
$0.41
$6.67
Volume
1.19 million shs
Average Volume
2.30 million shs
Market Capitalization
$255.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Epizyme MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
130.3% Upside
$3.50 Price Target
Short Interest
Healthy
3.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
-0.34mentions of Epizyme in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

366th out of 1,283 stocks

Pharmaceutical Preparations Industry

158th out of 615 stocks

Epizyme logo

About Epizyme (NASDAQ:EPZM) Stock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Analyst Ratings Changes

A number of equities research analysts have commented on EPZM shares. Wedbush lowered Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. Cowen downgraded Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research note on Monday, June 27th. Cowen lowered Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price objective for the company. in a report on Monday, June 27th. StockNews.com raised Epizyme from a "sell" rating to a "hold" rating in a report on Monday, July 25th. Finally, HC Wainwright decreased their price objective on Epizyme from $8.00 to $6.00 and set a "buy" rating for the company in a report on Friday, June 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $3.50.

Epizyme Stock Up 2.7 %

EPZM Stock opened at $1.52 on Friday. The business has a 50 day moving average of $1.15 and a 200-day moving average of $1.14. Epizyme has a 12-month low of $0.41 and a 12-month high of $6.67.

Epizyme (NASDAQ:EPZM - Get Rating) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Epizyme had a negative return on equity of 2,459.33% and a negative net margin of 614.08%. The business had revenue of $8.70 million during the quarter, compared to analysts' expectations of $10.86 million. During the same quarter last year, the business posted ($0.69) EPS. As a group, analysts expect that Epizyme will post -1.38 EPS for the current year.

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock News Headlines

Epizyme (NASDAQ:EPZM) Lifted to Hold at StockNews.com
Epizyme shares soar 60% on acquisition news
See More Headlines

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Company Calendar

Last Earnings
5/10/2022
Today
8/07/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+130.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-251,120,000.00
Net Margins
-614.08%
Pretax Margin
-613.94%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Book Value
($0.54) per share

Miscellaneous

Free Float
128,940,000
Market Cap
$255.86 million
Optionable
Optionable
Beta
-0.41

Key Executives

  • Mr. Grant C. Bogle (Age 64)
    Pres, CEO, Principal Financial Officer & Director
    Comp: $923.32k
  • Dr. Jeffery L. Kutok M.D. (Age 55)
    Ph.D., Chief Scientific Officer
    Comp: $646.13k
  • Dr. H. Robert Horvitz
    Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang
    Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Jerald Korn J.D. (Age 43)
    Chief Operating Officer
  • Mr. Joseph Beaulieu (Age 41)
    Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer
  • Mr. Craig West CFA
    VP of Investor Relations
  • Mr. John F. Weidenbruch (Age 61)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Tanja Weber
    Chief Bus. Officer
  • Dr. Mark A. De Rosch Ph.D. (Age 58)
    Chief Regulatory Officer













EPZM Stock - Frequently Asked Questions

Should I buy or sell Epizyme stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Epizyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View analyst ratings for Epizyme
or view top-rated stocks.

What is Epizyme's stock price forecast for 2022?

5 equities research analysts have issued 12-month target prices for Epizyme's shares. Their EPZM stock forecasts range from $1.50 to $6.00. On average, they expect Epizyme's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 130.3% from the stock's current price.
View analysts' price targets for Epizyme
or view top-rated stocks among Wall Street analysts.

How has Epizyme's stock price performed in 2022?

Epizyme's stock was trading at $2.50 at the beginning of 2022. Since then, EPZM stock has decreased by 39.2% and is now trading at $1.52.
View the best growth stocks for 2022 here
.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Epizyme
.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The biopharmaceutical company earned $8.70 million during the quarter, compared to the consensus estimate of $10.86 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 614.08%. During the same quarter in the previous year, the business posted ($0.69) EPS.

What other stocks do shareholders of Epizyme own?

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.20%) and FNY Investment Advisers LLC (0.03%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme
.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $1.52.

How much money does Epizyme make?

Epizyme (NASDAQ:EPZM) has a market capitalization of $255.86 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251,120,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Epizyme have?

Epizyme employs 250 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Epizyme is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at monique@thrustsc.com, or via fax at 617-349-0707.

This page (NASDAQ:EPZM) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.